% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Ehnert:268774,
author = {Ehnert, Sabrina and Hauser, Stefan and Hengel, Holger and
Höflinger, Philip and Schüle, Rebecca and Lindig, Tobias
and Baets, Jonathan and Deconinck, Tine and de Jonghe, Peter
and Histing, Tina and Nüssler, Andreas K and Schöls,
Ludger and Rattay, Tim},
title = {{V}itamin {D}3 deficiency and osteopenia in spastic
paraplegia type 5 indicate impaired bone homeostasis.},
journal = {Scientific reports},
volume = {14},
number = {1},
issn = {2045-2322},
address = {[London]},
publisher = {Macmillan Publishers Limited, part of Springer Nature},
reportid = {DZNE-2024-00318},
pages = {7335},
year = {2024},
abstract = {Hereditary spastic paraplegia type 5 (SPG5) is an autosomal
recessively inherited movement disorder characterized by
progressive spastic gait disturbance and afferent ataxia.
SPG5 is caused by bi-allelic loss of function mutations in
CYP7B1 resulting in accumulation of the oxysterols
25-hydroxycholesterol and 27-hydroxycholesterol in serum and
cerebrospinal fluid of SPG5 patients. An effect of 27-
hydroxycholesterol via the estrogen and liver X receptors
was previously shown on bone homeostasis. This study
analyzed bone homeostasis and osteopenia in 14 SPG5 patients
as a non-motor feature leading to a potential increased risk
for bone fractures. T-Scores in CT bone density measurements
were reduced, indicating osteopenia in SPG5 patients.
Further, we analyzed various metabolites of bone homeostasis
by ELISA in serum samples of these patients. We identified a
lack of vitamin D3 metabolites (Calcidiol and Calcitriol),
an increase in Sclerostin as a bone formation/mineralization
inhibiting factor, and a decrease in cross-linked
N-telopeptide of type I collagen (NTX), a marker indicating
reduced bone resorption. As statin treatment has been found
to lower oxysterol levels, we evaluated its effect in
samples of the STOP-SPG5 trial and found atorvastatin to
normalize the increased sclerostin levels. In summary, our
study identified osteopenia as a non-motor feature in SPG5
and suggests the need for vitamin D3 substitution in SPG5
patients. Sclerostin may be considered a therapeutic target
and biomarker in upcoming therapeutical trials in SPG5.},
keywords = {Humans / Mutation / Spastic Paraplegia, Hereditary:
genetics / Spastic Paraplegia, Hereditary: metabolism /
Oxysterols / Paraplegia / Homeostasis / Vitamin D:
therapeutic use / Oxysterols (NLM Chemicals) / Vitamin D
(NLM Chemicals)},
cin = {AG Gasser / AG Hauser / AG Schöls},
ddc = {600},
cid = {I:(DE-2719)1210000 / I:(DE-2719)1210016 /
I:(DE-2719)5000005},
pnm = {353 - Clinical and Health Care Research (POF4-353) / 352 -
Disease Mechanisms (POF4-352)},
pid = {G:(DE-HGF)POF4-353 / G:(DE-HGF)POF4-352},
typ = {PUB:(DE-HGF)16},
pmc = {pmc:PMC10973513},
pubmed = {pmid:38538623},
doi = {10.1038/s41598-024-53057-5},
url = {https://pub.dzne.de/record/268774},
}